# Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer

> **NCT04110769** · NA · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Genetic Change
- Chemotherapy Effect
- Pancreatic Cancer

## Interventions

- **DIAGNOSTIC_TEST:** next generation sequencing
- **DIAGNOSTIC_TEST:** following next generation sequencing

## Key facts

- **NCT ID:** NCT04110769
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-17
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04110769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04110769, "Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04110769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*